Current Opinion in Urology was launched in 1991. It is one of a successful series of review journals whose unique format is designed to provide a systematic and critical assessment of the literature as presented in the many primary journals. The field of urology is divided into 12 sections that are reviewed once a year. Each section is assigned a Section Editor, a leading authority in the area, who identifies the most important topics at that time. Here we are pleased to introduce the Journal's Editors and Section Editors for this issue.
Johannes W. Vieweg
Johannes W. Vieweg, MD, received his medical degree from the Technical University of Munich, Germany. In 1999, he completed the Duke urology residency program and subsequently enjoyed a nine-year tenure as Vice Chair of Research in the Duke Department of Urology, USA. In 2006, he joined the University of Florida (UF), USA, as the founding Professor and Chairman of the Department of Urology. Other positions held by Dr Vieweg during his 10-year tenure at UF include: The Wayne and Marti Huizenga Endowed Research Scholar Chair, Executive Director of the UF Prostate Disease Center, Chairman of the Florida Prostate Cancer Advisory Council and Vice President of the University of Florida Clinical Practice Association. In February 2015, the National Academy of Sciences in Washington D.C., awarded Dr Vieweg with a prestigious Jefferson Science Fellowship. In this position, Dr Vieweg frequently participated in diplomatic meetings with foreign governments to advance partnerships and implement foreign policy for the United States of America. In February 2017, Dr Vieweg was appointed as Professor and founding Dean of the Kiran C. Patel College of Allopathic Medicine at Nova Southeastern University in Fort Lauderdale, USA. Much of Dr Vieweg's career-long scientific activity has centered on the investigation and clinical testing of genetically engineered tumor vaccines, the discovery of universal tumor antigens and the modulation of immunosuppressive T cells and myeloid cells. He also made significant contributions by discovering novel pathway-targeted interventions and developing novel prediction models for therapeutic response. More recent research interests are aligned with the field of public health, prevention medicine, implementation science, and comparative effectiveness research in academic and community-based settings. Dr Vieweg's scientific work has received uninterrupted funding by the National Institute of Health since 1998 and is well documented in more than 180 publications, books, commentaries, and review articles.
Shahrokh F. Shariat
Dr Shahrokh F. Shariat is currently Professor and Chairman of the Department of Urology, Medical University of Vienna, Austria. He is also adjunct Professor of Urology and Medical Oncology at Weill Cornell Medical Center, USA, and adjunct Professor of Urology at the University of Texas Southwestern Medical Center, USA. He has published more than 816 peer-reviewed research papers, more than 160 non-peer-reviewed research papers, and 14 book chapters. In addition, he is the holder of four patents stemming from his research into prostate and bladder cancer and is the recipient of various national and international rewards. He is currently spearheading several collaborative multicenter groups (Bladder Cancer Research Consortium, The Bladder Cancer Detection Group, and The Upper Tract Urothelial Carcinoma Collaboration) and prospective clinical trials. He is a member of various academic societies and a journal, meeting abstract, and grant reviewer for numerous national and international organizations. He is an editorial board member of several journals including European Urology, BJU International, World Journal of Urology, Current Opinion in Urology, Immunotherapy, and Journal of Men's Health among others. His research focuses on urologic oncology - molecular mechanisms, markers, early detection, natural history, treatment, translational and outcomes research. More significantly, Dr Shariat has been working on the discovery, testing, and validation of molecular markers associated with the biological and clinical behavior of prostate and urothelial cancers. His laboratory research focuses on integrative genomics and epigenomics of urothelial carcinoma with the goal of designing personalized therapeutic strategies.
Professor Alexandre Mottrie, MD, PhD, graduated in 1988 from the School of Medicine at the Catholic University of Leuven, Belgium. He completed his residency in 1994 at the Johannes Gutenberg University of Mainz, Germany, where he was a staff member until 1996. Afterwards, he served as a fellow in Washington University Saint-Louis, USA, for six months to improve his laparoscopic skills. Since 1996, he has been a Urologist in the O.L.V.- Clinic in Aalst, Belgium. On the 5th December 2011, he successfully defended his PhD in the University of Saarland, Homburg-Saar, Germany. His major urological interests are urological oncology and minimal invasive surgery. He is a pioneer in robotic surgery and started this type of surgery in 2001. He has developed different types of robotic surgery. His department has become a training centre in the fields of laparoscopic and robotic surgery and he has trained numerous colleagues in the field of robotic surgery. With over 4000 robotic procedures, he has one of the largest experiences in the robotics field. In 2010, Dr Mottrie founded the ORSI-Academy, a multidisciplinary school of robotic and minimal-invasive surgery.
Dr Mottrie is scientifically very involved. He has authored multiple scientific papers and organised several international congresses and masterclasses in these fields. He has been actively involved in several congresses to perform live-surgery, given courses and presented state-of-the-art lectures. He is the Scientific Director of the ERUS-congresses, the president of the EAU Robotic Urology Section (ERUS), past-president of the Society of Robotic Surgeons (SRS) and the past-president of the Belgian Laparoscopic Urology Group (BLUG). He is also Associate Professor in the University of Saarland, Homburg-Saar, and the University of Ghent, Belgium. In 2015, he received the Golden Telescope Award at the Hamlyn Symposium in London for lifetime achievements in the robotic field. He is editor of the surgery-in-motion section of European Urology.
Paolo Dell’Oglio, MD, graduated in July 2012 with a final score of 110/110 magna cum laude and merit mention at the School of Medicine and Surgery Vita - Salute San Raffaele University, Italy. From July 2013 until September 2018 he was Urology resident at the Department of Urology of San Raffaele University Hospital, under the supervision of Professor Francesco Montorsi. During this time, he was also involved in the basic and clinical research on prostate cancer at the Urological Research Institute (URI) of San Raffaele Hospital, under the supervision of Professor Alberto Briganti.
From January 2015 to December 2015 he was research fellow at the Cancer Prognostics and Health Outcomes Research Unit, University of Montreal Health Center, Canada, under the supervision of Professor Pierre I. Karakiewicz. During this year he developed a special interest for urological oncology and elaborated advanced statistical computing that allowed him to analyse clinical databases and publish several scientific articles in high-impact factor journals with a particular focus on prostate, kidney and bladder cancer. During his studies, Dr Dell’Oglio developed a growing interest in minimally invasive surgery. In 2017 he completed his annual robotic clinical fellowship at the Department of Urology Institut Mutualiste Montsouris, France, under the supervision of Professor Xavier Cathelineau. During this fellowship he underwent intensive training in advanced laparoscopic and robotic surgeries (radical prostatectomy, radical and partial nephrectomy, radical cystectomy). Dr Dell’Oglio completed his residency in September 2018 with the final score of 70/70 magna cum laude. In 2018 he started a robotic fellowship at O.L.V. Hospital, Aalst, Belgium, under the supervision of Professor Alexandre Mottrie. During this fellowship he is performing advanced robotic surgeries (radical prostatectomy, radical and partial nephrectomy, radical cystectomy, simple prostatectomy, salvage lymph node dissection, colposacropexy) and intermediate procedures such as holmium laser enucleation of the prostate. He is director and trainer of the training courses in robotic surgery at O.L.V. Robotic Surgery Institute (ORSI) Academy.
Dr Dell’Oglio has authored 125 original articles published in high-impact factor journals (H-index 18). He has been actively involved in several plenary sessions at the European and American urological congresses. He is an associate of the European Association of Urology (EAU) Guidelines Office since 2017 and he is actively involved in several systematic reviews undertaken by the EAU Prostate Cancer Panel.
Dr Dell’Oglio is also member of the following professional societies: European Association of Urology (EAU), American Urological Association (AUA) and Italian Urological Society (SIU).